You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis

Article info

Article menu
XML
Case report
Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis

Authors

  • Sara Bjursten Department of Oncology, Institute of Clinical Sciences, University of Gothenburg Sahlgrenska Academy, Goteborg, SwedenDepartment of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden PubMed articlesGoogle scholar articles
  • Ankur Pandita Department of Oncology, Institute of Clinical Sciences, University of Gothenburg Sahlgrenska Academy, Goteborg, SwedenDepartment of Oncology, Sahlgrenska University Hospital, Goteborg, SwedenDepartment of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden PubMed articlesGoogle scholar articles
  • Zhiyuan Zhao Department of Oncology, Institute of Clinical Sciences, University of Gothenburg Sahlgrenska Academy, Goteborg, SwedenDepartment of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden PubMed articlesGoogle scholar articles
  • Charlotta Fröjd Department of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden PubMed articlesGoogle scholar articles
  • Lars Ny Department of Oncology, Institute of Clinical Sciences, University of Gothenburg Sahlgrenska Academy, Goteborg, SwedenDepartment of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden PubMed articlesGoogle scholar articles
  • Christer Jensen Department of Neuroradiology, Sahlgrenska University Hospital, Goteborg, Sweden PubMed articlesGoogle scholar articles
  • Tobias Ullerstam Department of Anesthesiology and Intensive Care, Sahlgrenska University Hospital, Goteborg, Sweden PubMed articlesGoogle scholar articles
  • Henrik Jespersen Department of Oncology, Institute of Clinical Sciences, University of Gothenburg Sahlgrenska Academy, Goteborg, SwedenDepartment of Oncology, Sahlgrenska University Hospital, Goteborg, SwedenDepartment of Oncology, Akershus University Hospital, Lorenskog, Norway PubMed articlesGoogle scholar articles
  • Jan Borén Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden PubMed articlesGoogle scholar articles
  • Malin Levin Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden PubMed articlesGoogle scholar articles
  • Henrik Zetterberg Department of Psychiatry and Neurochemistry, University of Gothenburg Institute of Neuroscience and Physiology, Goteborg, SwedenClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Goteborg, SwedenDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UKUK Dementia Research Institute, UCL, London, UK PubMed articlesGoogle scholar articles
  • Anna Rudin Department of Rheumatology and Inflammation Research, Institute of Medicine, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden PubMed articlesGoogle scholar articles
  • Max Levin Department of Oncology, Institute of Clinical Sciences, University of Gothenburg Sahlgrenska Academy, Goteborg, SwedenDepartment of Oncology, Sahlgrenska University Hospital, Goteborg, SwedenDepartment of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Max Levin; max.levin{at}wlab.gu.se
View Full Text

Citation

Bjursten S, Pandita A, Zhao Z, et al
Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis
Journal for ImmunoTherapy of Cancer 2021;9:e002732. doi: 10.1136/jitc-2021-002732

Publication history

  • Accepted June 10, 2021
  • First published July 2, 2021.
Online issue publication 
November 02, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.